Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis.

ABSTRACT:

Objective

Originator intravenous rituximab is an important rheumatology treatment but is costly, and administration requires several hours. Because biosimilar rituximab may cost less and subcutaneous rituximab requires a shorter visit, both may reduce costs and increase treatment capacity (infusions per year).

Methods

We implemented time-driven activity-based costing (TDABC), a method to assess costs and opportunities to increase capacity, throughout the care pathway for 26 patients receiving a total of 30 rituximab infusions. Using the TDABC estimates, we created a base case, which included provider time, salaries, infusion rates and times, and drug formulation, to simulate an induction cycle (two infusions). We varied these parameters in sensitivity analyses and assessed t

SUBMITTER: Wallace ZS 

PROVIDER: S-EPMC7231514 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature